文献速递妇科肿瘤

mTOR抑制剂vistusertib联合阿那曲唑治疗激素受体阳性复发或转移性子宫内膜癌的安全性与疗效:VICTORIA多中心、开放标签、1/2期随机临床试验

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

VICTORIA研究为多中心、开放标签、随机1/2期临床试验,2016年4月至2019年10月从法国12个癌症中心入组75例激素受体阳性复发或转移性子宫内膜癌患者,按2:1随机分配至vistusertib联合阿那曲唑组(V+A组)或阿那曲唑单药组(A组)。结果显示V+A组8周无进展率67.3% vs A组39.1%,总缓解率24.5% vs 17.4%,中位无进展生存期5.2个月 vs 1.9个月,不良事件可控。

要点

  • V+A组8周无进展率为67.3%,A组为39.1%。
  • V+A组总缓解率24.5%,A组为17.4%。
  • V+A组中位无进展生存期5.2个月,A组为1.9个月。

核心结论

  • 在激素受体阳性复发或转移性子宫内膜癌患者中,阿那曲唑联合vistusertib较阿那曲唑单药改善了8周无进展率、总缓解率和无进展生存期,且不良事件可控。
  • 识别分子亚组可能有助于更精确地筛选最可能获得良好结局的患者。

研究设计与样本

  • VICTORIA研究为多中心、开放标签、随机1/2期临床试验,2016年4月至2019年10月从法国12个癌症中心入组75例激素受体阳性复发或转移性子宫内膜癌患者。
  • 安全导入期后采用Simon两阶段设计,数据分析时间为2020年12月11日至2021年3月11日。
  • 患者按2:1随机分配至口服vistusertib(125 mg每日两次,每周2天)联合口服阿那曲唑(1 mg每日)组(V+A组)或口服阿那曲唑单药组(A组)。
  • 75例随机患者中73例接受治疗(中位年龄69.5岁,范围37-88岁,均为女性):V+A组49例,A组24例。

主要发现

  • V+A组8周无进展率为67.3%(单侧95%CI,54.7%),A组为39.1%(单侧95%CI,22.2%)。
  • V+A组总缓解率为24.5%(95%CI,13.3%-38.9%),A组为17.4%(95%CI,5.0%-38.8%)。
  • 中位随访27.7个月时,V+A组中位无进展生存期为5.2个月(95%CI,3.4-8.9),A组为1.9个月(95%CI,1.6-8.9)。
  • 安全导入期(V+A组n=6)未报告显著的严重不良事件。
  • 与vistusertib相关的最常见(≥2级)不良事件为疲乏、淋巴细胞减少、高血糖和腹泻。

关键数值与推荐

  • 主要终点:安全导入期的严重不良事件和2期经盲法独立中心审查评估的8周无进展率。
  • 次要终点:客观缓解率、缓解持续时间、无进展生存期、总生存期和不良事件发生率。

临床怎么用

  • 作者认为,在阿那曲唑基础上加用vistusertib改善了子宫内膜癌患者的8周无进展率、总缓解率和无进展生存期,且不良事件可控。
  • 作者提出,识别分子亚组可能有助于更精确地筛选最可能获得良好结局的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor with endocrine therapy. OBJECTIVE: To evaluate the safety and efficacy of vistusertib in combination with anastrozole in the treatment of women with hormone receptor-positive recurrent or metastatic endometrial cancer. DESIGN, SETTINGS, AND PARTICIPANTS: The VICTORIA study was a multicenter, open-label, randomized clinical trial that accrued 75 patients with hormone receptor-positive recurrent or metastatic endometrial cancer from 12 cancer centers in France in April 2016 to October 2019. After a safety run-in period, a Simon 2-stage design was used. Data analyses were performed from December 11, 2020, to March 11, 2021. INTERVENTIONS: Patients were randomized in a 2:1 ratio to oral vistusertib (125 mg twice daily 2 days per week) and oral anastrozole (1 mg daily) in the combination vistusertib with anastrozole arm (V+A arm) or oral anastrozole alone (A arm). MAIN OUTCOMES AND MEASURES: The primary end point was serious adverse events for the safety run-in period and progression-free rate at 8 weeks (8wk-PFR)-assessed with a blinded independent central review in phase 2. The secondary end points were objective response rate, duration of response, progression-free survival (PFS), overall survival, and incidence of adverse events. RESULTS: Of the 75 patients who were randomized, 73 (median [range] age, 69.5 [37-88] y; all female) were treated: V+A arm, 49 patients; A arm, 24 patients. In the V+A arm, the 8wk-PFR was 67.3% (unilateral 95% CI, 54.7%) and in the A arm, 39.1% (unilateral 95% CI, 22.2%). No significant serious adverse events were reported during the safety run-in period (n = 6 in V+A arm). The overall response rate was 24.5% (95% CI, 13.3%-38.9%) in the V+A arm vs 17.4% (95% CI, 5.0%-38.8%) in the A arm. With a median follow-up of 27.7 months, median PFS was 5.2 (95% CI, 3.4-8.9) in the V+A arm and 1.9 (95% CI, 1.6-8.9) months in the A arm. Fatigue, lymphopenia, hyperglycemia, and diarrhea were the most common (grade ≥2) adverse events associated with vistusertib. CONCLUSIONS AND RELEVANCE: This multicenter, open-label, phase 1/2 randomized clinical trial demonstrated that adding vistusertib to anastrozole improved 8wk-PFR, overall response rate, and PFS for patients with endometrial cancer and had manageable adverse events. Identification of molecular subgroups would allow for more precise selection of patients who may be most likely to experience favorable outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02730923.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Heudel P, Frenel JS, Dalban C, et al. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35551299. doi:10.1001/jamaoncol.2022.1047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。